JP2004536615A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536615A5
JP2004536615A5 JP2003517263A JP2003517263A JP2004536615A5 JP 2004536615 A5 JP2004536615 A5 JP 2004536615A5 JP 2003517263 A JP2003517263 A JP 2003517263A JP 2003517263 A JP2003517263 A JP 2003517263A JP 2004536615 A5 JP2004536615 A5 JP 2004536615A5
Authority
JP
Japan
Prior art keywords
cells
cell
vaccine
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003517263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536615A (ja
Filing date
Publication date
Priority claimed from PCT/IT2001/000419 external-priority patent/WO2003012085A1/en
Application filed filed Critical
Publication of JP2004536615A publication Critical patent/JP2004536615A/ja
Publication of JP2004536615A5 publication Critical patent/JP2004536615A5/ja
Pending legal-status Critical Current

Links

JP2003517263A 2001-07-30 2002-07-25 抗原提示細胞、その調製方法およびその癌ワクチンのための使用 Pending JP2004536615A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
PCT/IT2002/000488 WO2003012086A1 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Publications (2)

Publication Number Publication Date
JP2004536615A JP2004536615A (ja) 2004-12-09
JP2004536615A5 true JP2004536615A5 (https=) 2006-01-05

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517263A Pending JP2004536615A (ja) 2001-07-30 2002-07-25 抗原提示細胞、その調製方法およびその癌ワクチンのための使用

Country Status (16)

Country Link
US (3) US20030119187A1 (https=)
EP (1) EP1412485B1 (https=)
JP (1) JP2004536615A (https=)
KR (1) KR100916670B1 (https=)
CN (1) CN100591762C (https=)
AT (1) ATE505533T1 (https=)
AU (1) AU2002334387B2 (https=)
BR (1) BR0211520A (https=)
CA (1) CA2453522C (https=)
DE (1) DE60239741D1 (https=)
DK (1) DK1412485T3 (https=)
ES (1) ES2367256T3 (https=)
HU (1) HUP0401753A3 (https=)
MX (1) MXPA04000885A (https=)
PL (1) PL211907B1 (https=)
WO (2) WO2003012085A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN1910284B (zh) * 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
JP4925033B2 (ja) * 2004-02-03 2012-04-25 学校法人 久留米大学 ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
GB0700058D0 (en) * 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2510086A4 (en) * 2009-12-08 2013-05-22 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
PL2729008T3 (pl) * 2011-07-07 2017-10-31 Res Cancer Institute Of America Systemy, sposoby i formulacje do leczenia raka
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
HRP20200521T1 (hr) * 2012-10-30 2020-08-07 Mei Pharma, Inc. Kombinacijske terapije za liječenje kemorezistentnih rakova
US9562219B2 (en) * 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185811A (zh) * 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
CA2302316A1 (en) * 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Similar Documents

Publication Publication Date Title
JP2004536615A5 (https=)
US11981923B2 (en) Pepmixes to generate multiviral CTLS with broad specificity
Gustafsson et al. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
CN100591762C (zh) 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途
CA2796379A1 (en) Method for proliferation of antigen-specific t cells
CN107109364A (zh) 缺氧与常氧交替条件下的骨髓浸润淋巴细胞的激活
JP2006020648A5 (https=)
Lee et al. The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma
KR20130103492A (ko) 수지상 세포를 제조하기 위한 조성물 및 방법
AU2006288348A1 (en) Method for activation treatment of antigen-presenting cell
MX2022006547A (es) Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
Luo et al. Human amniotic fluid stem cells suppress PBMC proliferation through IDO and IL-10-dependent pathways
AU2011291477B2 (en) Cells expressing Th1 characteristics and cytolytic properties
CN101313061A (zh) 扩增双阴性t细胞的方法
JP2012504948A5 (https=)
Aloysius et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs
Gel’m et al. Functional activity of lymphocytes of healthy donors and cancer patients after culturing with IL-2 and IL-15
Moyer et al. Early vaccination with tumor lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects
Kuriyama et al. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination
Shao et al. Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy
JP4111394B2 (ja) 改変標的化t細胞の製造方法及び医薬
JP6782503B1 (ja) 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法
Yan et al. Killing effect of interleukin-13 receptor alpha 2 (IL-13Rα2) sensitized DC–CTL cells on human glioblastoma U251 cells
HK40084539A (en) Pepmixes to generate multiviral ctls with broad specificity
HK40020879B (en) Pepmixes to generate multiviral ctls with broad specificity